An observational study in Osteoporosis, sponsored by Tomidahama Hospital. Status unknown at 1 site in Japan. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-11-25.
Sponsored by Tomidahama Hospital · Observational
In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of denosumab in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.
The main objective of this study is to investigate effects of denosumab. The researchers also investigate the effects of Effects of previous osteoporotic therapy to denosumab treatment. In this study, the investigators analyse the determinants of subsequent BMD increase and fracture preventing effect by teriparatide.
Registry criteria: Patients treated in the investigators hospital using denosumab. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (\< young adult mean 65%).
Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants
1,675 studies on the registry are indexed under Osteoporosis; 211 are open to participants now.
This study's planned enrollment of 500 is above the median of 180 across 461 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Tomidahama Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Osteoporotic patients who admit to our hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
every 6 month injection
Also known as: Prolia
BMD increase by denosumab in Japanese
The investigators evaluate BMD increase by denosmab in Japanese patients.
Time frame: Up to 48 months
The determinants related to BMD increase and fracture prevention for denosumab treatment
The investigators evaluated lumbar and femoral neck BMD. The investigators evaluated baseline patients characteristics. The investigators will evaluate the relationship between BMD increase or fracture and patients characteristics using univariate and multivariate analysis.
Time frame: Up to 48 months
Effects of previous therapy to denosumab
The investigators evaluate effects of previous osteoporosis treatment to denosumab in BMD increase and bone turnover marker response using univariate and multivariate analysis.
Time frame: Up to 48 months
This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tomidahama Hospital